

Resource Summary Report

Generated by [RRID](#) on Aug 24, 2026

pcDNA3.1_ spike_del19

RRID:Addgene_155297

Type: Plasmid

Proper Citation

RRID:Addgene_155297

Plasmid Information

URL: <http://www.addgene.org/155297>

Proper Citation: RRID:Addgene_155297

Insert Name: SARS-Cov2 spike_deleted

Organism: SARS-Cov2

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:34547465](#)

Vector Backbone Description: Vector Backbone:pcDNA3.1; Vector Types:Generation of SARS-CoV-2-pseudotyped lentiviral particles; Bacterial Resistance:Ampicillin

Plasmid Name: pcDNA3.1_ spike_del19

Relevant Mutation: Deletion in C-term 19 aa of spike

Record Creation Time: 20220422T221851+0000

Record Last Update: 20260815T080800+0000

Ratings and Alerts

No rating or validation information has been found for pcDNA3.1_ spike_del19.

No alerts have been found for pcDNA3.1_ spike_del19.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Civita S, et al. (2025) Nanoscale engagement of programmed death ligand 1 (PD-L1) in membrane lipid raft domains of cancer cells. *The FEBS journal*.

Harfoot R, et al. (2025) Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro. *Antimicrobial agents and chemotherapy*, 69(8), e0170024.

Nielsen IH, et al. (2024) Cell-targeted gene modification by delivery of CRISPR-Cas9 ribonucleoprotein complexes in pseudotyped lentivirus-derived nanoparticles. *Molecular therapy*. *Nucleic acids*, 35(4), 102318.

Ho CL, et al. (2024) Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens. *Frontiers in immunology*, 15, 1340645.

Quaranta P, et al. (2024) SARS-CoV-2 Infection Alters the Phenotype and Gene Expression of Adipocytes. *International journal of molecular sciences*, 25(4).

Zhang M, et al. (2023) Incorporation of noncanonical base Z yields modified mRNA with minimal immunogenicity and improved translational capacity in mammalian cells. *iScience*, 26(10), 107739.

Montgomerie I, et al. (2023) Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. *iScience*, 26(4), 106256.

Unali G, et al. (2023) Interferon-inducible phospholipids govern IFITM3-dependent endosomal antiviral immunity. *The EMBO journal*, 42(10), e112234.

Miluzio A, et al. (2023) Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2. *EBioMedicine*, 87, 104390.

LeBlanc EV, et al. (2022) The green tea catechin EGCG provides proof-of-concept for a pan-coronavirus attachment inhibitor. *Scientific reports*, 12(1), 12899.

Ugalde AP, et al. (2022) Autophagy-linked plasma and lysosomal membrane protein PLAC8 is a key host factor for SARS-CoV-2 entry into human cells. *The EMBO journal*, 41(21), e110727.

Torres JL, et al. (2022) Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. *Proceedings of the National Academy of Sciences of the United States of America*, 119(20), e2120976119.

Villa A, et al. (2022) DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. *Pharmacological research*, 175, 105982.

Rebendenne A, et al. (2022) Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs. *Nature genetics*, 54(8), 1090.

Favalli A, et al. (2022) Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. *Frontiers in immunology*, 13, 873195.

Chiu CH, et al. (2022) Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities. *Frontiers in cellular and infection microbiology*, 12, 862656.

Francesconi O, et al. (2022) Synthetic carbohydrate-binding agents neutralize SARS-CoV-2 by inhibiting binding of the spike protein to ACE2. *iScience*, 25(5), 104239.

Vikurthi R, et al. (2022) Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. *Nature microbiology*, 7(7), 974.

Ou T, et al. (2021) Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. *PLoS pathogens*, 17(1), e1009212.

Mishra T, et al. (2021) SARS CoV-2 Nucleoprotein Enhances the Infectivity of Lentiviral Spike Particles. *Frontiers in cellular and infection microbiology*, 11, 663688.